Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates are useful to increase cardiolipin synthesis and for the treatment of Barth Syndrome, diabetic myopathy, cardiomyopathy associated with aging, mitochondrial disease, and other conditions and disorders where cardiolipin deficiency plays a causative or symptomatic role.